Geographic Atrophy

Low vision rehabilitation was associated with statistically significant increases in the overall composite score of a vision-related quality of life scale.

The latest episode of New Insight with Veeral Sheth, MD features an insightful conversation with David Eichenbaum, MD on his goals in mentoring the next generation of retina specialists, sharing anecdotes about his own journey in ophthalmology.

From a novel acne cream to a breakthrough depression drug, a half-dozen agent decisions are coming through in the coming 6 months.

At ARVO 2023, 24-month data suggests the change from baseline in GA lesion growth consistently favored pegcetacoplan vs. sham across subgroups in DERBY and OAKS trials.

As part of our ARVO 2023 coverage, Dr. Sheth sat down with Pravin Dugel, MD, President of Iveric Bio to discuss avacincaptad pegol for geographic atrophy and a look back at Dr. Dugel's career and his transition into industry.

Eyes treated with pegcetacoplan showed a significantly slower GA lesion progression rate compared with sham, and slower growth rate toward the fovea.